Developments in Medical Science that are making an insurance risk taker both Optimistic and worried

Explore two major developments in medical science that could reshape insurance risk management: GLP-1 drugs for diabetes and obesity, and Multi-Cancer Early Detection (MCED) tests. This session examines the efficacy, safety, and long-term implications of GLP-1 treatments, their impact on mortality, morbidity, and healthcare costs, and the promise and challenges of MCED tests for early cancer detection. Learn how these innovations could influence underwriting, claims, and product design for life and health insurers.